ALNY vs. TECH: Alnylam Pharmaceuticals vs. Bio-Techne Stock Comparison

November 11, 2026

How do Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Company profile comparison for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Profile Item	ALNY	TECH
Name	Alnylam Pharmaceuticals, Inc.	Bio-Techne Corp.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	20.89 billion USD	11.43 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	June 1, 2004	February 9, 1989
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ALNY

TECH

GSPC

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Total Return (1Y)	-64.57%	27.56%
Total Return (3Y, Annualized)	-1.58%	9.11%
Total Return (5Y, Annualized)	-3.13%	-9.91%

Risk Profile

Drawdown History

ALNY

TECH

GSPC

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Volatility (1Y, Annualized)	54.08%	43.08%
Beta (5Y)	0.45	1.26
Max Drawdown (5Y)	-68.25%	-65.87%
Avg. Volume (3M)	1.90M	2.81M

Risk-Adjusted Performance

Risk-Return Positioning

ALNY and TECH are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Sharpe Ratio (1Y)	-1.27	0.54
Sortino Ratio (1Y)	-1.45	0.82

Profitability

ROE (TTM)

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Bio-Techne (TECH) at 8.33% also sits in the top quartile.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

ALNY: 138.07%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.33%

Max: 109.18%
TECH: 8.33%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Bio-Techne (TECH) at 14.00% also retains a top-quartile share.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

ALNY: 52.85%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.00%

Max: 18.05%
TECH: 14.00%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Alnylam Pharmaceuticals (ALNY) at 23.72% operates in the top operating margin quartile, ahead of Bio-Techne (TECH) at 12.21%, which runs around its industry’s norm.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Max: 83.12%
ALNY: 23.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.21%

Max: 83.12%
Q3: 14.77%
TECH: 12.21%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
ROE (TTM)	138.07%	8.33%
ROA (TTM)	9.51%	6.38%
Net Margin (TTM)	52.85%	14.00%
Operating Margin (TTM)	23.72%	12.21%
Gross Margin (TTM)	77.28%	66.23%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Bio-Techne (TECH) at -0.38% is closer to the peer norm — faster top-line expansion for ALNY.

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Revenue Growth (YoY)	65.19%	-0.38%
Revenue Growth (3Y CAGR)	52.98%	2.25%
EPS Growth (YoY)	--	152.17%
EPS Growth (3Y CAGR)	--	-12.97%

Financial Strength

Current Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Max: 25.13
Q3: 12.13
Median: 5.52
ALNY: 2.48
Q1: 2.47
Min: 0.10

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.28

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
TECH: 2.28
Min: 0.10

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Techne (TECH) at 0.13 carries an industry-typical debt-to-equity mix, while Alnylam Pharmaceuticals (ALNY) at 0.83 uses more debt funding than most peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Max: 1.42
ALNY: 0.83
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.13

Max: 1.42
Q3: 0.65
Median: 0.15
TECH: 0.13
Q1: 0.02
Min: 0.00

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Current Ratio (MRQ)	2.48	2.28
Debt / Equity (MRQ)	0.83	0.13
Net Debt / EBITDA	-0.57	-0.20

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.44%

TECH: 0.44%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.59%

TECH: 27.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
Dividend Yield (TTM)	0.00%	0.44%
Dividend Payout Ratio (TTM)	0.00%	27.59%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
ALNY: 7.88
Min: 0.07

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

62.74

Max: 85.34
TECH: 62.74
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Bio-Techne (TECH) at 9.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Max: 58.18
Q3: 25.77
Median: 7.30
ALNY: 4.17
Q1: 3.01
Min: 0.01

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.31

Max: 58.18
Q3: 25.77
TECH: 9.31
Median: 7.30
Q1: 3.01
Min: 0.01

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Max: 13.53
Q3: 6.54
ALNY: 5.79
Median: 3.25
Q1: 1.69
Min: -5.59

TECH

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.28

Max: 13.53
Q3: 6.54
TECH: 5.28
Median: 3.25
Q1: 1.69
Min: -5.59

Alnylam Pharmaceuticals (ALNY) vs. Bio-Techne (TECH): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Alnylam Pharmaceuticals (ALNY) and Bio-Techne (TECH)
Metric	ALNY	TECH
P/E Ratio (TTM)	7.88	62.74
P/S Ratio (TTM)	4.17	9.31
P/B Ratio (MRQ)	5.79	5.28
Free Cash Flow Yield (TTM)	1.57%	2.39%